Jaguar Health vs Zhengye Biotechnology Holding
Zhengye Biotechnology Holding is the larger business, with $16.2m of revenue in fiscal 2025 against $11.5m for Jaguar Health (1.4 times as much). Jaguar Health grew faster (-1.5% against -37.5%). Zhengye Biotechnology Holding kept more of each dollar of sales as profit: a net margin of -60.0% against -465.4%.
| Latest fiscal year | Jaguar HealthJAGX, 2025 | Zhengye Biotechnology HoldingZYBT, 2025 |
|---|---|---|
| Revenue | $11.5m | $16.2m |
| Revenue growth | -1.5% | -37.5% |
| Net income | −$53.6m | −$9.7m |
| Operating margin | -398.8% | -60.6% |
| Net margin | -465.4% | -60.0% |
| Return on equity | — | -26.0% |
| Free cash flow | −$23.7m | $1.7m |
| Cash | $968,000 | $7.2m |
| Total debt | $42.5m | $10.7m |
| Debt to equity | — | 29.9% |
| Dividend per share | — | — |
| Dividend yield | — | 3.5% |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $439,515 | $61.6m |
| Price vs our value range | — | Above our value range |
| Moat score | 32 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |